Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AGEN

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1][2]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory and commercial prospects [1]. - Shareholders who purchased shares during the specified class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for November 5, 2024 [2]. - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to the alleged misleading statements by Agenus Inc. [3].